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Kathryn B. Garber1,*Long-Term Epigenetic Consequences to Famine
In the late stages ofWorldWar II, Germany imposed a food
embargo on The Netherlands, giving rise to a famine
known as the Dutch Hunger Winter. Although this was
a very unfortunate circumstance, the health-care and birth
registries that were maintained during that time provide
a valuable resource for examining the effects of famine
on human development. These registries allowed the
discovery that prenatal exposure to famine increases the
risk of certain complex traits, including coronary artery
disease and schizophrenia. Heijmans et al. provide a piece
of data that hints at the involvement of epigenetics in
these associations. They identiﬁed individuals who were
born around the time of the Dutch Hunger Winter and
used blood samples from these people—who are now in
their sixties—to look for long-term methylation differ-
ences as a consequence of the famine. Comparing methyl-
ation levels at the IGF2 imprinted locus in same-sex
siblings—one conceived during the famine and one who
was born before or conceived after the famine—they found
a small but signiﬁcant reduction in methylation at the
IGF2 differentially methylated region. These differences
were observed only when the mothers went hungry early
in fetal development; children conceived before the fam-
ine who had a late gestational exposure had IGF2 methyl-
ation levels similar to those of their control siblings. This
supports the idea that epigenetic marks are sensitive to
environmental forces very early in development and that
these exposures could have long-lived consequences that
can be observed molecularly. Whether this explains any
of the famine-associated risks of complex disease remains
to be seen.
Heijmans et al. Proc. Natl. Acad. Sci. 105, 17046–17049.
10.1073/pnas.0806560105.
Genome Shuffle in Cultured ES Cells
When you make a new knockout mouse line, you have to
assume that the knockouts differ from the parental strain
only at the gene of interest; otherwise, you could be chasing
down a red herring. Because you start with embryonic stem
cells from an inbred line, this seems like a pretty safe
assumption. New data from Liang et al. suggest that we
may need to be somewhat wary of copy number variationThe America(CNV) that arises during culturing of mouse embryonic
stem (ES) cells. They used comparative genomic hybridiza-
tion to compare 24 different germline-competent ES cell
clones with their parental lines and found that there were
1–2 Mb deletions or duplications in seven of them. Even
with relatively few cell divisions in culture, appreciable
CNV gains or losses arose during these mitotic divisions,
and these CNVs could be transmitted to the germline along
with the targeted mutation. Some recurrent CNVs were
identiﬁed in the study because they arose in subclones
from different parental ES cell lines. Sequence analysis at
the breakpoints suggests that these events are mediated
by related sequences surrounding the CNVs. Not only are
the mitotically derived CNVs that were observed in this
study something to watch out for in mouse work, they
open the question as to what might happen in human
embryonic stem cells when they are in culture. They also
hint at the idea that mitotically arising CNVs might yield
more somatic variation in the genome than we might
have thought.
Liang et al. Proc. Natl. Acad. Sci. 105, 17453–17456.
10.1073/pnas.0805638105.
Arabidopsis Uses Transcription to Prevent
Transcription
The portion of the eukaryotic genome that encodes
proteins is quite small, but we’ve recently recognized that a
major portion of the genome is actually transcribed. The
role of this widespread transcription is as yet unknown. In
Arabidopsis, at least, Wierzbicki et al. found that some of
these transcripts silence overlapping and nearby genes.
The transcripts they studied are produced by the plant-
speciﬁc RNA polymerase Pol V, and at the silenced sites,
they mediate repressive chromatin modiﬁcations that im-
pede transcription by the RNA polymerases II and III. Pol
V seems to work in a promoter-independent fashion, so
the selection of its targets is not understood. Once the tran-
scripts are produced, however, they are necessary but not
sufﬁcient for the observed gene silencing; siRNA produc-
tion is also required. Because we don’t have Pol V in our
cells, it remains to be seen whether any of the transcribed
noncoding regions in our DNA have a similar role in gene
regulation. These results do help explain the contradictory
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transcription to maintain transcriptional silencing in het-
erochromatic regions.
Wierzbicki et al. Cell 135, 635–648. 10.1016/
j.cell.2008.09.035.
Chromosome 11p15 Abnormalities in
Nonsyndromic Wilms Tumor
Scott et al. report chromosome11p15defects ina signiﬁcant
proportion of people with nonsyndromic Wilms tumor,
and the ﬁnding has important implications for these
patients and their families. The imprinted chromosome
11p15 region is well known for its association with growth
disturbance, particularly Beckwith-Wiedemann syndrome
(BWS). Individuals with BWS are at increased risk of the
childhood renal tumor Wilms tumor, but the association
of constitutional abnormalities of this region with nonsyn-
dromicWilms tumor was not appreciated previously. In 3%
of the sporadic cases andone familial case of nonsyndromic
Wilms tumor in the study, an abnormality was identiﬁed.
In most cases, the defect was either paternal uniparental
disomy or hypermethylation of the H19 differentially
methylated region (DMR). However, an atypical H19 DMR
microdeletion and the ﬁrst example of an H19 DMRmicro-
insertionwere also identiﬁed.Hypermethylationassociated
with the H19 DMR defects was found on only a proportion
of the mutated alleles, at least in the blood, but this mosai-
cismdoesnot appear to explainwhy thephenotype in these
individuals was limited to Wilms tumor. Bilateral tumors
were much more common in the individuals with an
11p15 defect, leading the authors to propose that an evalu-
ation of this chromosomal region be performed for all
individualswithWilms tumor to allow their risk of a contra-
lateral tumor to be assessed and also to provide better risk
assessment for their relatives.
Scott et al. NatureGenetics 40,1329–1334. 10.1038/ng.243.662 The American Journal of Human Genetics 83, 661–662, DecemAML Genome Sequence
The Philadelphia chromosome in chronic myelogenous
leukemia, gene ampliﬁcation of HER2 in breast cancer,
mismatch repair mutations in Lynch syndrome—we
know several cytogenetic and molecular defects that are
key to the initiation or progression of particular types of
cancer. But some types of cancer, such as acute myeloid
leukemia (AML), have been reticent in revealing their
underlying genetic causes. Even genome-wide approaches
to studying AML, including comparative genomic hybrid-
ization and single nucleotide polymorphism arrays, have
yielded very little information on AML pathogenesis. Ley
et al. thus decided to use a method of brute force, made
possible by recent developments in sequencing technol-
ogy, to identify some of these changes. Through sequence
comparisons of a cytogenetically normal tumor genome
with that of the patient’s constitutional genome, they
identiﬁed somatic mutations that arose in the tumor of a
patient with AML. Many of the more than 63,000 single-
nucleotide differences that resulted from this comparison
were either in nongenic regions or were found in a
sequence database, but eight of the single-nucleotide
variants that were predicted to alter gene function were
validated as somatic mutations. Four of these changes
occurred in genes that belong to gene families known to
be involved in cancer pathogenesis, but the other four
have not previously been implicated in cancer. In all cases,
these mutations were present at a frequency of ~50% in
the tumor genome, so it is believed they are found in vir-
tually all tumor cells in a heterozygous state. They are
thus believed to have arisen very early in carcinogenesis
and to be ‘‘drivers’’ of this pathologic process, making
them some of the ﬁrst candidate genes for involvement
in AML initiation.
Ley et al. Nature 456, 66–72. 10.1038/nature07485.ber 12, 2008
